# A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.

> **NCT04835805** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Genentech, Inc.** · enrollment: 65 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Belvarafenib
- **DRUG:** Cobimetinib
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT04835805
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-05-13
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04835805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04835805, "A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04835805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*